ClinicalTrials.gg

Program

JW0061

A development code. Also written as “JW0061 SAD” and “JW0061 MAD”.

Its studies are led by JW Pharmaceutical.

Furthest: phase 1, since Feb 23, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
JW Pharmaceutical11 open or runningphase 1since Feb 23, 2026Feb 23, 2026Dec 31, 2026phase 1 · NCT07514780

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2026First study: phase 1 study in HealthyFirst studyNCT07514780 · 104 planned · South Korea

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in HealthyNCT07514780

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07514780Healthy · South Korea1RecruitingDec 31, 2026104

How it is read

Names in the registry

  • “JW0061 SAD”, 1 entry
  • “JW0061 MAD”, 1 entry

Codes read as this program: JW0061.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.